Zymeworks, Inc. (ZYME)
29.47
-0.43
(-1.44%)
USD |
NASDAQ |
Sep 04, 11:31
Zymeworks Research and Development Expense (TTM) : 128.70M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 128.70M |
| March 31, 2026 | 135.72M |
| December 31, 2025 | 137.00M |
| September 30, 2025 | 142.83M |
| June 30, 2025 | 143.60M |
| March 31, 2025 | 138.32M |
| December 31, 2024 | 134.62M |
| September 30, 2024 | 123.08M |
| June 30, 2024 | 119.50M |
| March 31, 2024 | 129.75M |
| December 31, 2023 | 143.62M |
| September 30, 2023 | 171.06M |
| June 30, 2023 | 175.38M |
| March 31, 2023 | 192.00M |
| December 31, 2022 | 208.60M |
| September 30, 2022 | 210.49M |
| June 30, 2022 | 223.29M |
| March 31, 2022 | 217.98M |
| December 31, 2021 | 197.13M |
| September 30, 2021 | 181.53M |
| June 30, 2021 | 185.16M |
| March 31, 2021 | 173.67M |
| December 31, 2020 | 168.53M |
| September 30, 2020 | 174.66M |
| Date | Value |
|---|---|
| June 30, 2020 | 150.38M |
| March 31, 2020 | 134.95M |
| December 31, 2019 | 115.90M |
| September 30, 2019 | 84.60M |
| June 30, 2019 | 69.50M |
| March 31, 2019 | 61.08M |
| December 31, 2018 | 56.69M |
| September 30, 2018 | 54.62M |
| June 30, 2018 | 52.00M |
| March 31, 2018 | 44.92M |
| December 31, 2017 | 40.67M |
| September 30, 2017 | 36.31M |
| June 30, 2017 | 34.54M |
| March 31, 2017 | 36.48M |
| December 31, 2016 | 35.55M |
| September 30, 2016 | 35.88M |
| June 30, 2016 | 31.28M |
| March 31, 2016 | 28.20M |
| December 31, 2015 | 24.40M |
| September 30, 2015 | 18.44M |
| June 30, 2015 | 16.14M |
| March 31, 2015 | 12.13M |
| December 31, 2014 | 10.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Theravance Biopharma, Inc. | 24.46M |
| BridgeBio Pharma, Inc. | 505.38M |
| Aprea Therapeutics, Inc. | 6.721M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |